Table 3.

Overview of TEAEs.

n (%)	All
	(n = 73)
Any TEAE	73 (100)
Grade ≥3 TEAEs	58 (79.5)
Treatment-emergent SAEs	39 (53.4)
Drug-related treatment-emergent SAEs	22 (30.1)
TEAEs leading to deatha	7 (9.6)
TEAEs leading to permanent discontinuation of study treatment	14 (19.2)
TEAEs leading to premature study drug discontinuation	24 (32.9)
Bortezomib	13 (17.8)
Lenalidomide	11 (15.1)
Dexamethasone	4 (5.5)

^aTEAEs leading to death included listeremia (n = 1), progressive disease (n = 1), metastatic breast cancer (n = 1), metastatic melanoma (n = 1), COVID-19 (n = 2), diverticulitis (n = 1)

SAE, serious adverse event; TEAE, treatment-emergent adverse event.